Changchun High-Tech Subsidiary to Acquire Global Rights to Megestrol Acetate Oral Suspension for $30 Million

CLS··CNSGHU·Read original
3▲1 ▼0Impact / 5
Summary · why it matters

Changchun High-Tech Industries announced that GENSCI Singapore, a wholly owned subsidiary of its controlling subsidiary GeneScience Pharmaceuticals, plans to sign an agreement with Baosheng Pharmaceutical to acquire the intellectual property rights and marketing authorization holder rights for megestrol acetate oral suspension, known as Megace, in all regions worldwide except Hungary. The transaction amount is $30 million, with additional milestone payments of up to $70 million. The product has been included in the national medical insurance drug list.

Impact on assets 2

Financials▲
Others▲

Off-coverage companies 2

Changchun GeneScience Pharmaceutical Co., Ltd.i
Private± Mixedrelevance

GENSCI Singaporei
Private± Mixedrelevance